Clinical trials: Carcinoma, Small Cell, open to volunteers
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors…
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05802186
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.
- Trial name
- NCT06756217
- Testing
- 68Ga-grazytracer PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Trial name
- NCT07890246
- Testing
- IM-1340
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Non-Small Cell Lung Cancer, Pulmonary Metastases
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
This prospective, single-center, single-arm exploratory study will evaluate the safety and effectiveness of a pulsed field ablation system and a single-use pulsed field ablation catheter for the treatment of malignant lung…
- Trial name
- NCT07889297
- Testing
- Pulsed Field Ablation System and Single-Use Pulsed Field Ablation Catheter
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Chest Hospital
Small Cell Lung Carcinoma
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
- Trial name
- GUIDANCE (NCT06419179)
- Testing
- Durvalumab, Olaparib
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Lung Cancer, Non Small Cell Lung Cancer
The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it…
- Trial name
- NodeAI (NCT06540196)
- Testing
- NodeAI, Surgeon
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Local Advanced or Metastatic NSCLC
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
- Trial name
- NCT07294261
- Testing
- Garsorasib, Benmelstobart, Anlotinib, Benmelstobart, Anlotinib, Garsorasib, Cetuximab Beta Injection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or…
- Trial name
- NCT06956001
- Testing
- Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Small-cell Lung Cancer
SCLC Tarlatamab Blood Collection
The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC).
- Trial name
- NCT07468656
- Volunteers
- 25 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
This prospective, multicenter patient registry is designed to evaluate the effectiveness and safety of postoperative EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in patients with completely resected EGFR-mutant high-risk…
- Trial name
- NCT07837739
- Testing
- Adjuvant EGFR-TKI Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer
Lung cancer is a malignant tumor with high incidence and mortality in China and the world, among which small cell lung cancer (SCLC) accounts for 13% to 17% of lung cancer, and about 250,000 patients are diagnosed with SCLC every…
- Trial name
- NCT06462105
- Testing
- Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
- Volunteers
- 60 people
- Sponsor
- Zhou Chengzhi
EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
Osimertinib for Advanced EGFR-positive NSCLC Patients
Lung cancer is the leading cause of cancer incidence (11.6%) and mortality (18.4%) globally[1]. Development of targeted therapies in the context of precision medicine changed the way lung cancer was diagnosed and treated.
- Trial name
- NCT05037331
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University Hospital, Singapore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.